文献速递其他结缔组织病

EULAR ScleroID 在系统性硬化症中的交叉验证与变化敏感性

Cross-validation and sensitivity to change of EULAR ScleroID as a measure of function and impact of disease in patients with systemic sclerosis.
PubMed 文献 · RMD Open · 2025-10-10

基于 STRIKE 观察队列 271 例系统性硬化症患者,评估 EULAR ScleroID 在极早期、局限型和弥漫型亚型中的分布及反映临床严重度的价值。ScleroID 评分随亚型严重度递增,与临床指标和患者报告结局高度相关,并确定 12 个月内变化的最小临床重要差异阈值。

要点

  • ScleroID 评分中位数在极早期、局限型和弥漫型亚型中依次升高(p<0.001)。
  • 高疾病活动度患者 ScleroID 评分显著高于低疾病活动度患者(p=0.003)。
  • ScleroID 变化与临床指标及患者报告结局变化强相关,并确定 MCID 阈值。

核心结论

  • ScleroID 与验证过的临床指标强相关,对标准治疗下的变化有反应性,支持其在临床实践和试验中使用。
  • ScleroID 能捕捉系统性硬化症的多维负担,无论疾病亚型。

研究设计与样本

  • 研究纳入 STRIKE 观察队列中填写 ScleroID 问卷的系统性硬化症患者,共 271 例,其中极早期 69 例、局限型 139 例、弥漫型 63 例。
  • 变化值计算为 12 个月随访时与基线之间的差值,并与其他指标的最小临床重要差异(MCID)进行比较。

主要发现

  • ScleroID 评分中位数(IQR)在极早期、局限型和弥漫型亚型中分别为 2.1(3.6)、3.4(4.4)和 4.7(4),呈渐进性升高(p<0.001)。
  • 高疾病活动度患者的 ScleroID 评分显著高于低疾病活动度患者(p=0.003)。
  • 存在指端溃疡、肺部疾病或小肠细菌过度生长的患者,其相应领域的 ScleroID 评分均更高(p<0.005)。
  • ScleroID 评分及其相应领域与所有其他患者报告结局(PROs)均高度相关(p<0.05)。
  • ScleroID 的变化与临床指标及其他 PROs 的变化强相关,并针对 HAQ-DI、UCLA SCTC GIT 2.0 和 Cochin 手功能量表确定了 MCID 变化的具体阈值。

关键数值与推荐

  • ScleroID 评分中位数(IQR):极早期 2.1(3.6),局限型 3.4(4.4),弥漫型 4.7(4),三组比较 p<0.001。
  • 高疾病活动度患者 ScleroID 评分显著高于低疾病活动度患者(p=0.003)。
  • 指端溃疡、肺部疾病或小肠细菌过度生长患者相应领域评分更高(p<0.005)。
  • ScleroID 评分及其领域与所有其他 PROs 相关(p<0.05)。

临床怎么用

  • ScleroID 可用于临床实践中评估系统性硬化症患者的功能和疾病影响。
  • ScleroID 可用于临床试验中作为结局指标。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the distribution of the EULAR SSc Impact of Disease (ScleroID) and its domain questions in very early (Ve), limited (lc) and diffuse cutaneous (dc) subsets, its value in reflecting clinical severity, and to assess its sensitivity to change and minimal clinically important difference (MCID) in a 12-month interval. METHODS: Patients with ScleroID questionnaires from the observational cohort STRIKE were included in the study. Changes (Δ) were calculated as the difference between 12-month follow-up and compared MCIDs of the other measures. RESULTS: Data were available for 271 patients, 69 with Ve, 139 lc and 63 dc systemic sclerosis (SSc). Median (IQR) ScleroID scores were progressively higher in the 3 subsets with 2.1 (3.6) for VeSSc, 3.4 (4.4) for lcSSc and 4.7 (4) for dcSSc (p<0.001). ScleroID showed strong content validity against clinical measures. Patients with high disease activity had significantly higher ScleroID scores than low ones (p=0.003). Presence of digital ulcers, pulmonary disease or small intestinal bacterial overgrowth was all reflected in higher scores in their relative domains (p<0.005 for all). Accordingly, ScleroID scores and its relative domains showed high correlations with all other patient-reported outcomes (PROs) (p<0.05). Changes in ScleroID strongly correlated with changes in clinical measures and other PROs with specific thresholds identified for MCID changes in Health Assessment Questionnaire Disability Index, the University of California Los Angeles Scleroderma Clinical Trials Consortium gastrointestinal tract 2.0 and Cochin Hand Function Scale. CONCLUSION: ScleroID demonstrates strong correlation with validated clinical measures and responsiveness to changes in standard of care, supporting its use in both clinical practice and trials. ScleroID captures the multidimensional burden of SSc regardless of disease subsets.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Colak SY, Di Donato S, Bixio R, et al. Cross-validation and sensitivity to change of EULAR ScleroID as a measure of function and impact of disease in patients with systemic sclerosis. RMD Open. 2025. PMID: 41073110. doi:10.1136/rmdopen-2025-005999

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。